NCT05002244 is a Phase 1 clinical trial of CTL0801 (Azilsartan) in Health, Subjective, sponsored by Celltrion.

Who is sponsoring NCT05002244?

NCT05002244 is sponsored by Celltrion.

What drugs are being tested in NCT05002244?

Interventions in NCT05002244: CTL0801 (Azilsartan), CTL0802 (Rosuvastatin), CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin).

What condition does NCT05002244 study?

NCT05002244 studies Health, Subjective.

Is NCT05002244 still recruiting?

NCT05002244 is currently completed. Last updated 23 December 2021.

Last reviewed 2021-12-23 · How we verify

NCT05002244

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers

Completed Phase 1 Last updated 23 December 2021

What this trial tests

Phase 1 trial testing CTL0801 (Azilsartan) in Health, Subjective in 37 participants. Completed in 13 September 2021.

Timeline

23 July 2021

Primary endpoint
29 August 2021

13 September 2021

Quick facts

Lead sponsor	Celltrion
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	23 July 2021
Primary completion	29 August 2021
Estimated completion	13 September 2021
Sites	1 location across South Korea

Drugs / interventions tested

CTL0801 (Azilsartan) — full drug profile →
CTL0802 (Rosuvastatin) — full drug profile →
CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin) — full drug profile →

Conditions studied

Health, Subjective — all drugs for Health, Subjective →

Sponsor

Celltrion — full company profile →

Who can join

Adults 19 to 50, any sex, with Health, Subjective. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two-arm, open-label, single-sequence, multiple-dose, cross-over phase 1 study to evaluate the interaction between two investigational drugs by comparing and analyzing the pharmacokinetic interaction and safety of CTL0801 and CTL0802 at steady state when administered alone or in combination with repeated oral doses in healthy adult volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Health, Subjective

Currently open trials in the same condition.

NCT07447440 — Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases · recruiting
NCT06829485 — Florida Community-Engaged Research Alliance (FL-CEAL) · NA · recruiting
NCT06392880 — Comparison of Floss Band Application and Mulligan Mobilization · NA · recruiting
NCT06575907 — Health, Functioning, Work, and Experiences of Social and Health Services of Persons With Stroke · active not recruiting
NCT05760001 — The IGNITE for Kids Study on Concentrated Investment in Black Neighborhoods and Child Health and Well-Being · NA · active not recruiting

Other Celltrion trials

Trials by the same sponsor.

NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
NCT07200986 — Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects · Phase 1 · active not recruiting
NCT07128654 — A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers · Phase 1 · completed
NCT07158346 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · completed
NCT06952478 — A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05002244 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Celltrion
Last refreshed: 23 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05002244.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing